CF
ATOS icon

Corebridge Financial’s Atossa Therapeutics ATOS Stock Holding History

Corebridge Financial’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-4,131
Closed -$41.7K – 254
2025
Q1 		$41.7K Sell
4,131
-61
-1% -$741 ﹤0.01% 2776
2024
Q4 		$59.4K Sell
4,192
-317
-7% -$6.19K ﹤0.01% 2781
2024
Q3 		$103K Sell
4,509
-28
-0.6% -$565 ﹤0.01% 2605
2024
Q2 		$81.7K Buy
+4,537
New +$100K ﹤0.01% 2706

Other funds holding ATOS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Corebridge Financial's ATOS Position: Q2 2025 in Review

Corebridge Financial sold out of Atossa Therapeutics (ATOS) in Q2 2025, closing a stake of 4,131 shares — an estimated $41.7K sold.

Corebridge Financial first reported a position in ATOS in Q2 2024 and held it in 4 quarters. The position peaked at $103K in Q3 2024. 84 funds tracked by Wall St. Rank hold ATOS as of Q2 2025.

  • Corebridge Financial reported no remaining Atossa Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 4,131 Atossa Therapeutics shares in Q2 2025, an estimated $41.7K.
  • Corebridge Financial first reported a position in Atossa Therapeutics in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Atossa Therapeutics position peaked at $103K in Q3 2024.
  • 84 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.